Wuxi Biologics has highlighted its highly integrated and scalable platform for the research, development and production of complex biologics.[1][2] Bi- and multi-specific modalities support the growth of the company.[1] It has launched a new WuXiUI™ bioprocessing platform, which is an ultra-intensive fed-batch solution for various CHO cell lines and other mammalian cells.[1][2] This platform increases productivity 3- to 6-fold over 14-day culture for monoclonal antibodies, bispecific antibodies, and recombinant proteins while maintaining product quality.[1][2] It reduces the cost of production of medicinal substances by 60-80% compared to traditional fed-batch processes in disposable bioreactors.[1][2] The platform is easily scalable without the need for new equipment and has a lower carbon footprint due to more efficient use of media and less waste.[1][2] Other platforms include WuXiUP™ for continuous production with yields above 110 g/L and PatroLabTM for digital twins with real-time monitoring.[4][5] The WuXiBody™ platform enables the assembly of bispecific constructs with low immunogenicity risk.[7]